

IVHEM 2020



INTERNATIONAL
VIRAL HEPATITIS
ELIMINATION
MEETING

VIRTUAL MEETING
4-5 DECEMBER 2020



PROGRAM BOOK

Table of Contents

Welcome	3
Meeting Information	4
Practical Information	5
Organizing Committee	6
Scientific Committee	7
Program	8
Acknowledgments	12



Welcome

Dear Colleagues,

Viral hepatitis affects more than 320 million people globally and presents the primary cause of liver cancer and the second leading cause of cancer deaths in the world.

Around 257 million people have chronic hepatitis B infection and 71 million have chronic hepatitis C infection. Combined they cause an estimated 1.3 million deaths annually. Despite there being cure for hepatitis C and a highly effective vaccine and treatment for hepatitis B most newborns remain unvaccinated and most persons with hepatitis B and hepatitis C are undiagnosed, not in care or receiving life-saving treatments.

Key issues that need to be addressed include how to mobilize communities and translate research outcomes into public health policy and clinical practice to meet the 2030 targets for hepatitis elimination.

During IVHEM experts in viral hepatitis from around the globe will examine current evidence on how to implement programs that improve the prevention of viral hepatitis, and increase the number of persons diagnosed, in care treated and cured of their infection before developing end stage liver disease and liver cancer. Bringing community organizations, researchers, public health practitioners and clinicians together into a community of practice, the IVHEM 2020 program includes practical examples of innovative intervention studies, effective strategies of national elimination programs and novel capacity building mechanisms for testing and treatment, all focusing on meeting the 2030 targets.

Huma Qureshi & John Ward

Meeting Chairs 2020



John Ward
MD

U.S. Centers of Disease
Control and Prevention
USA

Meeting Chair



Huma Qureshi
MD

Pakistan Medical
Research Council,
Pakistan

Meeting Chair



Meeting Information

Needs statement

The field of viral hepatitis prevention, testing and treatment is undergoing major changes and the potential for nations to achieve the 2030 elimination targets remains high. In 2021, IVHEM will focus on several topic areas to advance progress toward hepatitis elimination.

In 2021, Gavi will begin support of vaccination of newborns to prevent mother to child transmission of hepatitis B. Countries will report progress toward the 2020 interim performance targets set forth by WHO in the global strategy for hepatitis elimination. Programs in diverse settings have develop new strategies for testing and treatment. Lastly, the COVID-19 pandemic required most nations to redirect considerable health programs and clinical staff to meet this new health threat. Hepatitis elimination program are adapting to meet program objectives while assisting pandemic response.

IVHEM is a global forum for the exchange of practical experiences in the translation of immunization, diagnostic and therapeutic advances into broad applications that accelerate progress toward elimination of viral hepatitis as a public health threat. The program features outstanding international experts and leaders of national and local implementing programs that address strategies regarding testing and screening, care and cure, prevention, and innovative models to finance elimination strategies.


Meeting objectives

- Facilitate cross-disciplinary discussion on barriers and challenges to achieve the elimination of viral hepatitis;
- Provide a forum for knowledge exchange and discussion of practical experiences using new diagnostics and treatments to diagnose and manage viral hepatitis; and
- Provide a toolbox for practical application of research and development, for evidence-based policymaking.

Learning objectives

After participating in this activity, the participants will:

- Identify innovative strategies for hepatitis b and hepatitis C testing and linkage to care and how these can be applied to their program and clinical activities;
- Recognize the needs from a public health perspective and respond to these needs by reshaping their policymaking approaches;
- Further develop new or strengthen already existing foundations for political commitment, national planning, and program improvements; and
- Translate the latest research and technologies into clinical policy and practice for delivering an adequate continuum of viral hepatitis services.



Practical Information

Abstracts

Accepted abstracts are published in **Reviews in Antiviral Therapy & Infectious Diseases, Volume 2020_11**.

You can download the abstract book here.

Certificate of attendance

Certificates of attendance will be sent via email upon completion of the post-meeting survey.

Feedback

Your feedback is very valuable to us and enables us to further improve this meeting. After each session a short questionnaire will pop-up and we would like ask you to take a minute to complete it. After the meeting, a survey will be send to you via email, with other questions to improve this meeting.

Group Picture

We ask you all to take a photo of yourself and send it to the IVHEM secretariat at rikke@vironet.com or karin@vironet.com. They will stitch it all together and send out the finished virtual group photo at the end of the meeting.

Networking – Meeting Hub

The Meeting Hub allows you to connect and communicate with other attendees. Once you have located an attendee you want to connect with, click the Connect button. Once the other attendee accepts your request, you can choose to interact by starting a live chat or live video call. You can also schedule a meeting at a later time, send messages and take notes. Contact information for all attendees you have connected with will be included when you export your contacts.

Notes

You will be able to take notes during the virtual meeting. Any notes that you take throughout the meeting can be exported by selecting the Export icon in the top right of the screen near your Profile image. In additional, all Meeting Hub connections you have make with other OnAIR participants will save their contact information, that you can export using the Export option as well.

OnAIR

OnAIR is the virtual meeting platform being used for IVHEM 2020. A video tutorial on how to use the Meeting Portal can be found [here](#)

Presentations and webcasts



Webcasts of the presentations along with the PDF presentations will be posted as webcasts on

www.AcademicMedicalEducation.com shortly after the meeting.

Poster Gallery & Poster Viewing

Friday 4 December, 6:00 PM CET Odd Poster Numbers

Saturday 5 December, 6:00 PM CET Even Poster Numbers

On the virtual meeting portal you will also be able to find the Poster Gallery. Here you can view all of the exciting posters and “star” those you would like to visit during the live Poster Viewing Sessions. The Poster Gallery can be visited at any time.

Social Media

We encourage you to post news about IVHEM to your social media accounts and tweet about IVHEM as often as you like during the conference. You can either post your own tweet to your followers using the hashtag **#IVHEM** or retweet a message through the official **@Virology_Edu** account.

Technical Problems

Should you encounter any technical problems, please contact us at rikke@vironet.com or karin@vironet.com.

Time Zones

Times are in Central European Time CET. If you need to convert the times to your timezone, this website might be of interest to you:

<https://www.worldtimebuddy.com/>

Disclaimer: This workshop aims to offer participants the opportunity to share information. The Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the conference.

Organizing Committee



Huma Qureshi
MD
Pakistan Medical Research Council,
Pakistan



John Ward
MD
John Ward, MD
Coalition for Global Hepatitis
Elimination, Centers for Disease
Control and Prevention (CDC);
Emory University, United States




Charles Boucher
MD, PhD
Erasmus Medical Center
The Netherlands



Manal El-Sayed
MD, PhD
Ain Shams University
Egypt



Missing, Jordan Feld, MD,
MPH
Toronto Centre for Liver Disease,
Canada



Angelos Hatzakis
PhD, MSc
University of Athens
Greece



Jessica Howell
MBBS(Hons) FRACP PhD
Burnet Institute
Australia



Margaret Hellard
MBBS, FRACP, FAFPHM, PhD
Burnet Institute
Australia



Olufunmilayo Lesi
FWACP, FMCP
WHO HQ,
Switzerland



Michael Ninburg
Hepatitis Education Project
United States



Scientific Committee

Maia Butsashvili, MD, MS, PhD - Health Research Union, Georgia

Jude Byrne - Australian Injecting & Illicit Drug Users League, Australia

Vladimir Chulanov, MD, PhD, DSc - Central Research Institute of Epidemiology, Russia

Andrea Cox, MD, PhD - Johns Hopkins School of Medicine, United States

Khin Pyone Kyi - Myanmar Liver Foundation, Myanmar

Jeffrey Lazarus, PhD, MIH, MA - ISGlobal, Spain

Liudmyla Maistat - Medicines Patent Pool, Switzerland

Francesco Marinucci, PhD - Abbott, Switzerland

Shruti Mehta, PhD, MPH - Johns Hopkins School of Medicine, United States

Jean-Michel Pawlotsky, MD, PhD - Hôpital Henri Mondor, France

Homie Razavi, PhD, MBA - Center for Disease Analysis, United States

Tatjana Reic - European Liver Patients Association, Belgium

Marcelo Silva, MD - Austral University Hospital, Argentina

Our Team



Karin Siebelt
Team Leader



Victoria Sarasola
Project Coordinator



Rikke Rode
Project Coordinator



Lara da Silva Miguel
Project Coordinator



Roy Lisman
Technical Support

Email us:

General Information & Program:
Karin@vironet.com

Help Desk:
Rikke@vironet.com

FRIDAY, 4 DECEMBER 2020

Times are in Central European Time (CET)

Official Opening of the Meeting

- 2:00 PM **John Ward, MD**
Coalition for Global Hepatitis Elimination, Centers for Disease Control and Prevention (CDC);
Emory University, United States
Huma Qureshi, MD
Pakistan Medical Research Council, Pakistan

Opening Session **Where Are We in Our Attempt for Elimination?** *Chair: John Ward (United States)*

- 2:10 PM **WHO Efforts / Status on Global Elimination**
Meg Doherty, MD, MPH, PhD
World Health Organization, Switzerland
- 2:25 PM **Last Year's Key Developments Strengthening the Elimination Efforts**
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease / University Health Network, Canada

2:40 PM **Discussion**

2:55 PM Tea break

Session 1 **The Impact of COVID-19 on Hepatitis Elimination** *Chair: Jordan Feld (Canada)*

- 3:10 PM **The Impact of COVID-19 on Hepatitis Elimination (A Modelling Perspective)**
Shevanthi Nayagam, MD
Imperial College London, United Kingdom
- 3:20 PM **The Impact of COVID-19 on Hepatitis Elimination (Health Care Perspective)**
Saeed Hamid, MD, FRCP
The Aga Khan University, Pakistan
- 3:30 PM **Eliminating Viral Hepatitis: Perspectives From the South African Harm Reduction Community**
Andrew Scheibe, MBChB, Dip HIV Man, MPH
University of Pretoria, South Africa

Abstract - Driven Presentations:

- 3:40 PM The Effect of COVID-19 on the Hepatitis C Screening in Georgia Ana Aslanikashvili #36
- 3:45 PM A Model for Collaborative Care to Increase Testing and Treatment of HCV in a Shelter Population During COVID-19 (Canada) Nicola Gale #30
- 3:50 PM **Faculty Discussion: Challenges / Opportunities**



4:25 PM Tea Break

Session 2 Perinatal and Childhood Hepatitis - Symplification Strategies (Test-All)

Chair: Huma Qureshi (Pakistan)

4:40 PM **(Perinatal) Hepatitis B / Mother to Child Transmission**

Po-Lin Chan, MD

World Health Organization Western Pacific Regional Office, Philippines

4:55 PM **Hepatitis Coinfections in Childhood (B, C, and D), Their Diagnosis and Treatment**

Manal El-Sayed, MD, PhD

Ain Shams University, Egypt

Abstract - driven Presentations:

5:10 PM Healthcare Consumption in Addicted Versus Non-Addicted Hepatitis B and C Patients in the Netherlands Daan Von Den Hoff #2

5:15 PM Occult Hepatitis B Virus Infection among HIV Negative and Positive Isolated Anti-HBc Individuals in Eastern Ethiopia Ayana Desalegn Admassu #3

5:20 PM Seroprevalence and Associated Risk Factors for Hepatitis B Virus Infection Among Barbers and Their Clients in Two Cities of Cameroon Ngoupa Joël Brice #4

5:25 PM **Panel Discussion**

Perspective GAVI

Deepali Patel, MPH

GAVI, Switzerland

Country Experience: Thailand

Yong Poovorawan, MD

Chulalongkorn University, Thailand

Regional Experience: Africa

Olufunmilayo Lesi, FWACP, FMCP

WHO HQ, Switzerland

6:00 PM End of the First Day & Poster Discussions - Odd Numbered Posters

SATURDAY, 5 DECEMBER 2020

Times are in Central European Time (CET)

Welcome to Day 2

- 2:00 PM **John Ward, MD**
Coalition for Global Hepatitis Elimination, Centers for Disease Control and Prevention (CDC); Emory University, United States
- 2:05 PM **Mortality due to Hepatitis B and Hepatitis C: Findings from the Global Burden of Disease Study 2019**
Mae Dirac, MD
University of Washington / IHME, United States
- 2:20 PM **Q & A**

Session 3 **HBV and HCV Prevention, Care, and Treatment in Displaced Populations (Refugees / Migrants)** *Chair: Manal El-Sayed (Egypt)*

- 2:30 PM **Largest Refugee Population Rohingya, Bangladesh**
Mohammad Ali, MD
National Liver Foundation of Bangladesh, Bangladesh
- 2:40 PM **Largest Refugee Population in Africa - S. Sudanese, Uganda**
Ponsiano Ocama, MD, PhD
Makerere University, Uganda
- 2:50 PM **Can We Eliminate Viral Hepatitis Among Migrant Populations in Europe?**
Jeffrey Lazarus, PhD, MIH, MA
Barcelona Institute for Global Health ISGlobal, Spain

Abstract - Driven Presentations:

- | | | | |
|---------|--|----------------------|----|
| 3:00 PM | Challenge and Opportunity for HCV Elimination among Young PWID in New York City: Relatively Low RNA Seroconversion and Genetically Linked HCV Infections | Pedro Mateu-Gelabert | #5 |
| 3:05 PM | Cost Effectiveness of Expanding Treatment with Direct Acting Antiviral Treatment to Reduce Hepatitis C Incidence among HIV Infected MSM in Thailand | Shreoshee Mukherjee | #6 |
| 3:10 PM | Missed Opportunities for HCV Elimination in Provincial Correctional Institutions in Ontario, Canada | Paul loudovski | #7 |
| 3:15 PM | Reduction of Hepatitis C Burden in Islamabad, Pakistan Slums through CHW Screen and Treat Programs | Hassan Mahmood | #8 |

- 3:20 PM **Faculty Discussion**



3:50 PM Tea Break

Session 4 Ongoing Programs Focusing on Hep C Elimination

Chair: John Ward (United States)

4:05 PM **Hepatitis and COVID-19**

Faisal Sultan, MD

Ministry of National Health Services, Regulations & Coordination, Pakistan

4:15 PM **Cost-effective testing Hepatitis C - Diagnostic tool (FIND)**

Jagpreet Chhatwal, PhD

Harvard Medical School, United States

4:21 PM **Panel Discussion**

Country Experience: India

Gagandeep Singh Grover, MD

Health and Family Welfare, India

Country Experience: Egypt

Manal El-Sayed, MD, PhD

Ain Shams University, Egypt

Country Experience: Iceland (Abstract Number #10)

Ragnheidur Fridriksdottir, RN, MBA

Skåne University Hospital, Iceland

4:50 PM Tea Break

Session 5 Completing the Job Towards Elimination - Leaving No One Behind - Equity Is Needed

Chair: Michael Ninburg (United States)

5:05 PM **Achieving Health Equity Through Hepatitis Elimination**

John Ward, MD

Coalition for Global Hepatitis Elimination, Centers for Disease Control and Prevention (CDC); Emory University, United States

5:20 PM **Panel Discussion**

Country Experience: Uzbekistan

Homie Razavi, PhD, MBA

Center for Disease Analysis, United States

Country Experience: Thailand

Nasamon Wanlapakorn, MD, PhD

Chulalongkorn University, Thailand

Maria Buti, MD

Hospital Universitario Valle Hebron, Spain

5:50 PM **Closing of the Meeting**

John Ward, MD

U.S. Centers of Disease Control and Prevention / Coalition for Global Hepatitis Elimination, United States

Huma Qureshi, MD

Pakistan Medical Research Council, Pakistan

6:00 PM Poster Discussion - Even Numbered Posters

Acknowledgments

CORPORATE SUPPORT

PLATINUM LEVEL



GILEAD

CONTRIBUTOR LEVEL



FEROZSONS
LABORATORIES LIMITED



Acknowledgments

ENDORSED BY

